Drugs / Atirizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05760430 | Dec 2022 → Dec 2024 | hepatocellular carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Atirizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05760430 ↗ |
| Route | Intravenous | “Atirizumab+15 mg/kg of Bevacizumab was injected intravenously” NCT05760430 ↗ |